Morgan Stanley assumed coverage of Incyte (INCY) with an Equal Weight rating with a price target of $73, up from $68. The firm sees an improving set-up for shares approaching key data updates expected this year for mCALR and JAK2V617Fi in Myelofibrosis, and Phase II data for povorcitinib in asthma in the second half of 2025 presents an opportunity to further prove out the potential for povo beyond hidradenitis suppurativa, the analyst tells investors in a research note.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INCY:
- Incyte’s Future Hinges on Pipeline Potential Amid Jakafi Exclusivity Loss
- Incyte Announces New CEO William J. Meury
- Incyte’s Challenges and Potential Amid Leadership Change and R&D Hurdles
- Incyte’s Leadership Transition and Pipeline Uncertainty Justify Hold Rating
- Shell denies deal talks with BP, Micron reports Q3 beat: Morning Buzz